Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Serum voriconazole levels following administration via percutaneous jejunostomy tube.

Literature DB >> 14506064

Serum voriconazole levels following administration via percutaneous jejunostomy tube.

Valérie Martinez, Jean-Luc Le Guillou, Christian Lamer, Melissande Le Jouan, Michel Tod, Françoise Dromer.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2003 PMID： 14506064 PMCID： PMC201143 DOI： 10.1128/AAC.47.10.3375.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

× No keyword cloud information.

9 in total

1. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species.

Authors: P Belanger; C C Nast; R Fratti; H Sanati; M Ghannoum
Journal: Antimicrob Agents Chemother Date: 1997-08 Impact factor: 5.191

2. Effects of voriconazole on Candida glabrata in vitro.

Authors: A Koul; J Vitullo; G Reyes; M Ghannoum
Journal: J Antimicrob Chemother Date: 1999-07 Impact factor: 5.790

3. Nosocomial Candida glabrata colonization: an epidemiologic study.

Authors: J A Vazquez; L M Dembry; V Sanchez; M A Vazquez; J D Sobel; C Dmuchowski; M J Zervos
Journal: J Clin Microbiol Date: 1998-02 Impact factor: 5.948

4. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes.

Authors: D P Healy; M C Brodbeck; C E Clendening
Journal: Antimicrob Agents Chemother Date: 1996-01 Impact factor: 5.191

5. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection.

Authors: Russell E Lewis; Dimitrios P Kontoyiannis; Rabih O Darouiche; Issam I Raad; Randall A Prince
Journal: Antimicrob Agents Chemother Date: 2002-11 Impact factor: 5.191

6. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

Authors: M A Pfaller; S A Messer; R J Hollis; R N Jones; D J Diekema
Journal: Antimicrob Agents Chemother Date: 2002-06 Impact factor: 5.191

7. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.

Authors: M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal: Antimicrob Agents Chemother Date: 2002-04 Impact factor: 5.191

8. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Authors: L Purkins; N Wood; P Ghahramani; K Greenhalgh; M J Allen; D Kleinermans
Journal: Antimicrob Agents Chemother Date: 2002-08 Impact factor: 5.191

Review 9. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors: P L Fidel; J A Vazquez; J D Sobel
Journal: Clin Microbiol Rev Date: 1999-01 Impact factor: 26.132

9 in total

4 in total